27 August 2003
Use of drotrecogin alfa (activated) in two patients with severe sepsis
Małgorzata Mikaszewska-Sokolewicz, Małgorzata Nierebińska, Ewa Mayzner-ZawadzkaMed Sci Monit 2003; 9(8): CS80-87 :: ID: 13109
Abstract
Background:Severe sepsis is a disease associated with high mortality rates, which may be related to late diagnosis and institution of treatment, as well as unsatisfactory effectiveness of therapies used so far. Frequent monitoring of the patient’s clinical condition and laboratory results for early signs of sepsis and use of recombinant activated protein C can improve significantly the outcome of treatment.Case Report:The paper presents two patients with severe sepsis treated with drotrecogin alfa (activated). The first one, after multiorgan trauma, with renal failure due to crush injury, started to manifest gradually progressing symptoms of severe sepsis on 9th day of hospitalization in ICU. On 18th day, developing septic shock was diagnosed. As the initial standard therapy proved ineffective, it was decided to start recombinant human activated protein C (rhAPC). During infusion of the drug, dynamic improvement of organ function (respiratory and circulatory system, kidneys) and general condition of the patient was observed. The second patient, with rapidly progressing symptoms of septic shock and liver abscess confirmed as the source of infection, was subjected to therapy with Xigris® (Eli Lilly, USA) on the 2nd day of treatment in ICU, 12 hours after abscess drainage and compensation of blood platelet deficiency. This case also demonstrated rapid improvement of the patient’s condition and function of the organs involved by the disease (rapid stabilization of blood platelet count is notable).Conclusions:In both presented cases, the therapy with drotrecogin alfa (activated) was used due to lack of satisfactory response to initial standard treatment. Both cases indicate that the preparation is effective and safe.
Keywords: Anti-Infective Agents - therapeutic use, Multiple Organ Failure - drug therapy, Protein C - therapeutic use, Radiography, Thoracic, Recombinant Proteins - therapeutic use, Sepsis - drug therapy, Sepsis - mortality
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952